Does the media refer more to DYAI or KLRS?

In the previous week, Dyadic International and Dyadic International both had 4 articles in the media. Kalaris Therapeutics' average media sentiment score of 0.51 beat Dyadic International's score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kalaris Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DYAI or ATRA?

In the previous week, Dyadic International had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Atara Biotherapeutics. Dyadic International's average media sentiment score of 0.00 equaled Atara Biotherapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACRV or DYAI?

In the previous week, Dyadic International had 2 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.73 beat Dyadic International's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RLYB or DYAI?

Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 476.70%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media favor RLYB or DYAI?

In the previous week, Dyadic International had 3 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for Dyadic International and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.51 beat Dyadic International's score of 0.00 indicating that Rallybio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dyadic International (DYAI) Competitors

$0.52 +0.02 (+3.89%)

As of 09/4/2026 04:00 PM Eastern

Compare

DYAI vs. KLRS, ATRA, ACRV, OTLK, and RLYB

Should you buy Dyadic International stock or one of its competitors? Dyadic International's main competitors and comparable companies include Kalaris Therapeutics (KLRS), Atara Biotherapeutics (ATRA), Acrivon Therapeutics (ACRV), Oncobiologics (OTLK), and Rallybio (RLYB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dyadic International compare to Kalaris Therapeutics?

Dyadic International (NASDAQ:DYAI) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Dyadic International and Dyadic International both had 4 articles in the media. Kalaris Therapeutics' average media sentiment score of 0.51 beat Dyadic International's score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kalaris Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyadic International has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 476.70%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 380.77%. Given Dyadic International's higher probable upside, equities analysts plainly believe Dyadic International is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Dyadic International has higher revenue and earnings than Kalaris Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	6.13	-$7.36M	-$0.23	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 20.9% of Dyadic International shares are held by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kalaris Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Kalaris Therapeutics' return on equity of -71.71% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Summary

Kalaris Therapeutics beats Dyadic International on 9 of the 14 factors compared between the two stocks.

How does Dyadic International compare to Atara Biotherapeutics?

Dyadic International (NASDAQ:DYAI) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Dyadic International has a net margin of -201.43% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of -79.12% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

In the previous week, Dyadic International had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Atara Biotherapeutics. Dyadic International's average media sentiment score of 0.00 equaled Atara Biotherapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atara Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atara Biotherapeutics has higher revenue and earnings than Dyadic International. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	6.13	-$7.36M	-$0.23	N/A
Atara Biotherapeutics	$120.77M	0.81	$32.69M	-$1.18	N/A

Dyadic International currently has a consensus target price of $3.00, indicating a potential upside of 476.70%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential downside of 2.66%. Given Dyadic International's higher possible upside, equities analysts plainly believe Dyadic International is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Dyadic International has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 20.9% of Dyadic International shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Dyadic International and Atara Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Acrivon Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Acrivon Therapeutics' return on equity of -70.14% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Dyadic International	-201.43%	-2,920.31%	-84.77%

Acrivon Therapeutics presently has a consensus target price of $13.50, suggesting a potential upside of 533.80%. Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 476.70%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Dyadic International had 2 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.73 beat Dyadic International's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acrivon Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Dyadic International has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Dyadic International has higher revenue and earnings than Acrivon Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Dyadic International	$3.09M	6.13	-$7.36M	-$0.23	N/A

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Acrivon Therapeutics beats Dyadic International on 10 of the 15 factors compared between the two stocks.

How does Dyadic International compare to Oncobiologics?

Dyadic International (NASDAQ:DYAI) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Dyadic International has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Dyadic International currently has a consensus price target of $3.00, suggesting a potential upside of 476.70%. Oncobiologics has a consensus price target of $5.20, suggesting a potential upside of 680.20%. Given Oncobiologics' higher possible upside, analysts clearly believe Oncobiologics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Dyadic International has higher revenue and earnings than Oncobiologics. Dyadic International is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	6.13	-$7.36M	-$0.23	N/A
Oncobiologics	$1.35M	120.19	-$62.42M	-$0.77	N/A

Oncobiologics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Oncobiologics' return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Oncobiologics	N/A	N/A	-254.82%

In the previous week, Dyadic International had 4 more articles in the media than Oncobiologics. MarketBeat recorded 4 mentions for Dyadic International and 0 mentions for Oncobiologics. Dyadic International's average media sentiment score of 0.00 equaled Oncobiologics'average media sentiment score.

Company	Overall Sentiment
Dyadic International	Neutral
Oncobiologics	Neutral

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Dyadic International beats Oncobiologics on 9 of the 14 factors compared between the two stocks.

How does Dyadic International compare to Rallybio?

Rallybio (NASDAQ:RLYB) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Dyadic International has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	104.47	-$8.98M	-$4.34	N/A
Dyadic International	$3.09M	6.13	-$7.36M	-$0.23	N/A

90.3% of Rallybio shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 10.3% of Rallybio shares are held by insiders. Comparatively, 20.9% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dyadic International has a net margin of -201.43% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-40.53%	-38.13%
Dyadic International	-201.43%	-2,920.31%	-84.77%

In the previous week, Dyadic International had 3 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for Dyadic International and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.51 beat Dyadic International's score of 0.00 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 476.70%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rallybio has a beta of -0.85, suggesting that its share price is 185% less volatile than the broader market. Comparatively, Dyadic International has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

Dyadic International beats Rallybio on 11 of the 16 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.25M	$4.02B	$7.27B	$12.92B
Dividend Yield	N/A	3.60%	2.54%	8.90%
P/E Ratio	-2.26	12.65	272.43	25.42
Price / Sales	6.13	1,376.20	637.14	97.20
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	-7.43	16.15	12.85	6.17
Net Income	-$7.36M	-$22.76M	$3.47B	$349.50M
7 Day Performance	-15.29%	0.30%	0.97%	-0.15%
1 Month Performance	-46.34%	8.24%	5.47%	1.02%
1 Year Performance	-42.84%	49.08%	24.29%	14.50%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	1.9589 of 5 stars	$0.52 +3.9%	$3.00 +476.7%	-45.6%	$18.25M	$3.09M	N/A	7
KLRS Kalaris Therapeutics	2.3701 of 5 stars	$4.20 +2.4%	$18.75 +346.4%	-16.3%	$97.60M	N/A	N/A	110	News Coverage Positive News Analyst Upgrade
ATRA Atara Biotherapeutics	1.4471 of 5 stars	$9.84 +4.0%	$9.50 -3.5%	-23.8%	$94.96M	$120.77M	N/A	330	Insider Trade
ACRV Acrivon Therapeutics	3.0286 of 5 stars	$2.18 -0.9%	$13.50 +519.3%	+63.8%	$94.28M	N/A	N/A	58	Analyst Upgrade
OTLK Oncobiologics	3.1999 of 5 stars	$0.64 +5.1%	$4.65 +626.6%	-25.0%	$90.49M	$1.35M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. KLRS, ATRA, ACRV, OTLK, and RLYB

How does Dyadic International compare to Kalaris Therapeutics?

Summary

How does Dyadic International compare to Atara Biotherapeutics?

Summary

How does Dyadic International compare to Acrivon Therapeutics?

Summary

How does Dyadic International compare to Oncobiologics?

Summary

How does Dyadic International compare to Rallybio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. KLRS, ATRA, ACRV, OTLK, and RLYB

How does Dyadic International compare to Kalaris Therapeutics?

Does the media refer more to DYAI or KLRS?

Which has more volatility & risk, DYAI or KLRS?

Do analysts rate DYAI or KLRS?

Which has better earnings and valuation, DYAI or KLRS?

Do insiders & institutionals hold more shares of DYAI or KLRS?

Is DYAI or KLRS more profitable?

Summary

How does Dyadic International compare to Atara Biotherapeutics?

Is DYAI or ATRA more profitable?

Does the media refer more to DYAI or ATRA?

Which has stronger earnings & valuation, DYAI or ATRA?

Do analysts recommend DYAI or ATRA?

Which has more risk & volatility, DYAI or ATRA?

Do insiders & institutionals believe in DYAI or ATRA?

Summary

How does Dyadic International compare to Acrivon Therapeutics?

Is ACRV or DYAI more profitable?

Do analysts prefer ACRV or DYAI?

Does the media prefer ACRV or DYAI?

Which has more risk & volatility, ACRV or DYAI?

Which has stronger earnings and valuation, ACRV or DYAI?

Do insiders and institutionals hold more shares of ACRV or DYAI?

Summary

How does Dyadic International compare to Oncobiologics?

Which has more risk and volatility, DYAI or OTLK?

Do analysts prefer DYAI or OTLK?

Which has preferable earnings and valuation, DYAI or OTLK?

Is DYAI or OTLK more profitable?

Does the media refer more to DYAI or OTLK?

Do insiders & institutionals have more ownership in DYAI or OTLK?

Summary

How does Dyadic International compare to Rallybio?

Which has stronger valuation & earnings, RLYB or DYAI?

Do institutionals and insiders have more ownership in RLYB or DYAI?

Is RLYB or DYAI more profitable?

Does the media favor RLYB or DYAI?

Do analysts recommend RLYB or DYAI?

Which has more risk and volatility, RLYB or DYAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools